Neuren Pharmaceuticals Ltd has released a press release.
DAYBUE (trofinetide) 2024 net sales US$348 million
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Neuren receives Rare Pediatric Disease Designation from FDA
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Priority Review Voucher sale proceeds received
- Trofinetide marketing application submitted in Europe
- Neuren announces A$50m on-market share buy-back program
Later from Neuren Pharmaceuticals
- Appendix 4E and 2024 full year accounts
- 2024 results - A$166m comprehensive income for shareholders
- Neuren receives DAYBUE sales milestone payment of US$50m
- Neuren initiates development of NNZ-2591 to treat HIE
- NEU confirms primary endpoints for Phase 3 trial in PMS
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals